Diamond Hill Capital Management Inc. Has $316.14 Million Position in Labcorp Holdings Inc. $LH
Diamond Hill Capital Management Inc. has reduced its stake in Labcorp Holdings Inc. by 23.3% but still holds a significant position of 1.26 million shares valued at $316.14 million, making Labcorp its 20th-largest holding. Labcorp reported better-than-expected quarterly results, with EPS of $4.25 and revenue of $3.54 billion, and raised its FY2026 EPS guidance. The company also declared a quarterly dividend of $0.72 per share and maintains a "Moderate Buy" analyst rating with an average target price of $308.
Handelsbanken Fonder AB Increases Position in Labcorp Holdings Inc. $LH
Handelsbanken Fonder AB has increased its stake in Labcorp Holdings Inc. (NYSE:LH) by 17.4% in the fourth quarter, bringing its total holding to 32,199 shares valued at $8.08 million. This increase follows Labcorp's strong Q4 earnings, which beat expectations with $4.25 EPS on $3.54 billion revenue, and raised its FY2026 guidance. Analyst sentiment remains positive with a "Moderate Buy" consensus and a target price of $308.00, alongside a declared quarterly dividend of $0.72 per share.
Thermo Fisher’s New Sweden Lab Deepens Role In Global Drug Development
Thermo Fisher Scientific has opened a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, bolstering its global drug development services, especially for complex modalities like antibodies and cell therapies. This move aims to deepen its role as a partner to pharmaceutical and biotech companies, expanding its reach in the Nordic region and reinforcing its competitive position against peers. Despite recent share price volatility and debt concerns, the company is investing in core drug development services, and investors should monitor the lab's utilization and its impact on long-term customer relationships.
Illumina adds former Labcorp CEO to board of directors By Investing.com
Illumina Inc. has announced the election of David P. King, former chairman and CEO of Laboratory Corporation of America Holdings, to its board of directors, effective after the annual meeting. This move follows the retirement of three existing board members. The appointment comes as Illumina's shares trade near their 52-week high, supported by a "FAIR" financial health rating and robust gross profit margins, according to InvestingPro data.
David P. King elected to Illumina's Board of Directors
Illumina, Inc. has elected David P. King, former Chairman and CEO of Labcorp, to its Board of Directors to enhance its clinical strategy and integrate genomics into healthcare. King brings extensive experience in diagnostics, healthcare delivery, and board governance, which is expected to strengthen Illumina's long-term impact for patients, customers, and shareholders. His election follows the retirement of three other board members.
Labcorp Holdings Inc. stock outperforms competitors on strong trading day
Shares of Labcorp Holdings Inc. (LH) rose 1.47% to $257.42 on Wednesday, outperforming the broader market which also saw gains, with the S&P 500 Index up 1.08% and the Dow Jones Industrial Average up 1.31%. This strong performance puts Labcorp Holdings Inc. 12.36% shy of its 52-week high.
Strength in Danaher's Biotechnology Unit Seems Firm: More Upside Ahead?
Danaher Corporation's Biotechnology segment shows strong performance, with core revenues increasing 7% in Q1 2026 due to sustained momentum in bioprocessing and robust demand from pharmaceutical customers. Despite some headwinds in medical filtration and declining equipment demand, the company projects mid-single-digit core revenue growth for the segment in Q2 2026. Danaher's shares have declined recently, and its valuation is above the industry average, but its 2026 earnings estimate has seen an increase.
Labcorp launches AI-powered app for lab results tracking By Investing.com
Labcorp has launched MyLabcorp, an AI-powered mobile application designed to help users access, interpret, and track their lab test results. The app utilizes OpenAI models to provide personalized explanations, educational content, and tools for scheduling appointments. This initiative aims to deepen insights into health data, supporting more informed patient-provider conversations, and builds on Labcorp's significant market presence and recent strong financial performance.
Labcorp Launches MyLabcorp™, a New AI-Powered Mobile App Designed to Help Consumers Understand Lab Results and Track Health Trends Over Time
Labcorp has launched MyLabcorp™, an AI-powered mobile app designed to help consumers understand their lab results and track health trends over time. The app integrates lab results, AI-enabled insights, and educational content, leveraging OpenAI models for personalized explanations and conversational interactions. It aims to empower users with better health context and support more informed discussions with healthcare providers, all within a secure, HIPAA-compliant environment.
New Labcorp app uses OpenAI to explain your lab results
Labcorp has launched MyLabcorp, an AI-powered mobile app designed to help consumers understand their lab results and track health trends over time. The HIPAA-compliant app integrates Labcorp test results with OpenAI-powered explanations and clinically reviewed educational content. This initiative aims to address the growing consumer demand for clearer health information by providing personalized insights and facilitating more informed conversations with healthcare providers.
Labcorp Launches MyLabcorp™, a New AI-Powered Mobile App Designed to Help Consumers Understand Lab Results and Track Health Trends Over Time – Company Announcement - FT.com
Labcorp has launched MyLabcorp™, an AI-powered mobile app designed to help consumers understand their lab results and track health trends over time. The app utilizes OpenAI models to provide personalized explanations of results, offers clinically reviewed health education content, and allows users to manage lab services. This initiative aims to provide clearer health information and support more informed conversations between patients and healthcare providers.
Labcorp joins lab results personalization push with ‘MyLabcorp’ AI app
Labcorp has launched "MyLabcorp," a new mobile app that uses AI and clinical guidelines to help patients understand their lab test results and support better conversations with healthcare providers. The app aims to address the growing trend of consumers using AI for health information by providing curated, context-rich explanations and educational content. This move positions Labcorp among other diagnostic companies and healthcare platforms that are incorporating AI to personalize health insights for users.
Labcorp Holdings Inc. $LH Shares Sold by Gabelli Funds LLC
Gabelli Funds LLC reduced its stake in Labcorp Holdings Inc. by 19.4% in the fourth quarter, selling 8,000 shares. Insider selling also continued with executive vice presidents Brian J. Caveney and Der Vaart Sandra D. Van reducing their positions, bringing the total insider sales over the last quarter to 16,656 shares. Despite these sales, Labcorp beat quarterly earnings expectations, reporting EPS of $4.25 on $3.54 billion in revenue, and analysts maintain a "Moderate Buy" consensus with a target price of $308.
Labcorp stock (US50540R4092): New filing shows iA Global Asset Management bought shares
A new filing on May 19, 2026, reveals that iA Global Asset Management has purchased 7,609 shares of Labcorp (US50540R4092), a diagnostics company critical to U.S. healthcare infrastructure. Labcorp's business, which includes laboratory testing and drug development services, provides essential healthcare support and is influenced by patient testing activity, specialty diagnostics, and contract work. This institutional purchase signals continued interest in the defensive healthcare stock, emphasizing the company's role in the U.S. healthcare system and its growth drivers such as test volumes, payer dynamics, and network efficiency.
Thermo Fisher Scientific expands global biobank leadership through strategic collaboration with PRECISE-SG100K Singapore to advance population-scale proteomics
Thermo Fisher Scientific is collaborating with Precision Health Research, Singapore (PRECISE) to support its PRECISE-SG100K study, a major population-scale biobank initiative. This partnership focuses on advancing population-scale proteomics to improve disease detection, prevention, and personalized care. The collaboration will integrate Thermo Fisher's Olink® Proximity Extension Assay platforms and Orbitrap Astral mass spectrometry system with Seer’s Proteograph® Product Suite to provide comprehensive proteomic analysis, enabling the translation of biological data into new disease mechanisms and biomarker insights.
Onconetix Sets 1-for-10 Reverse Stock Split Effective
Onconetix (ONCO) announced a 1-for-10 reverse stock split to be effective May 21, 2026, primarily to regain compliance with Nasdaq's minimum bid price requirement. This action will reduce outstanding shares from 11.4 million to approximately 1.14 million, with proportional ownership maintained for shareholders. TipRanks’ AI Analyst, Spark, rates ONCO as Underperform due to significant financial difficulties, negative profitability, a bearish technical trend, and unfavorable valuation metrics.
Global Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG
The global Cell Culture Media Market is projected to grow from USD 3.7 billion in 2026 to USD 7.1 billion by 2036, driven by rising biologics production, expanding cell and gene therapy pipelines, and increasing adoption of serum-free formulations. Key players like Avantor, Thermo Fisher Scientific, and Lonza Group AG are focusing on scalable GMP production and advanced media platforms to meet demand. The serum-free media segment and cancer research application are expected to lead market growth, with China, Japan, and Germany showing the fastest regional expansion.
7,609 Shares in Labcorp Holdings Inc. $LH Purchased by iA Global Asset Management Inc.
iA Global Asset Management Inc. recently purchased 7,609 shares of Labcorp Holdings Inc. (NYSE:LH) worth approximately $1.91 million, establishing a new position in the company. This acquisition contributes to Labcorp's high institutional ownership, which stands at 95.94%. Other firms, including Goldman Sachs and First Trust Advisors, also increased their holdings in Labcorp, following the company's strong Q1 results, which surpassed analyst expectations in both EPS and revenue.
Onconetix (ONCO) Stock Surges Over 23% Overnight: Why Is It Moving?
Onconetix Inc. (ONCO) saw its shares surge over 23% in after-hours trading after reversing a significant regular session decline. This surge follows recent operational progress from its subsidiary Proteomedix AG, which reported positive clinical validation for its Proclarix blood test for prostate cancer. The company also initiated a U.S. validation trial, despite reporting negative earnings and a low market capitalization.
Thermo Fisher Sci. stock (US8835561023): Lab demand and U.S. biotech exposure stay in focus
Thermo Fisher Scientific remains a key U.S. life sciences stock due to its central role in the laboratory and biopharma supply chain. The company's performance is influenced by lab equipment demand, biopharma spending, and its broad product portfolio serving various sectors. Understanding Thermo Fisher's business model and market position offers insights into the broader scientific tools ecosystem and U.S. healthcare innovation.
Labcorp Holdings Inc. (LH) Stock Analysis: A 23.83% Upside Potential Beckons Investors
Labcorp Holdings Inc. (LH) shows strong investment potential with a 23.83% upside, according to analyst target prices, driven by its robust market position in diagnostics and innovative initiatives. Despite some unavailable valuation metrics, the company exhibits solid revenue growth, effective shareholder fund management, and positive analyst sentiment. Strategic collaborations and technological advancements, such as integrating generative AI, further enhance its competitive edge and growth prospects in the healthcare sector.
Labcorp Holdings Inc. stock underperforms Monday when compared to competitors despite daily gains
Labcorp Holdings Inc. (LH) stock increased by 2.06% on Monday, closing at $255.57. Despite this gain, the stock underperformed compared to its competitors amidst a mixed trading session where the Dow Jones Industrial Average rose and the S&P 500 Index declined. This rise ended a three-day losing streak for Labcorp.
TFX News | TELEFLEX INC (NYSE:TFX)
This article provides recent news and analysis for Teleflex Inc. (NYSE:TFX), including its current stock price and performance related to Q1 estimates, Q4 earnings, and a major divestiture plan. It also highlights the company's showcase of new clinical data for its UroLift™ System and Barrigel™ Rectal Spacer, and announces its quarterly dividend. Several entries from ChartMill also suggest TFX as a compelling value investment with strong fundamentals.
Baird Adjusts Price Target on Labcorp Holdings to $335 From $334, Maintains Outperform Rating
Baird has increased its price target for Labcorp Holdings (LH) to $335, up from $334, while reaffirming an Outperform rating on the stock. This adjustment comes amidst other analyst activities, including recent insider share sales and expanding collaborations for Labcorp. The company recently reported strong Q1 2026 earnings, raising its full-year outlook.
Labcorp Holdings Inc. $LH Shares Bought by DNB Asset Management AS
DNB Asset Management AS increased its stake in Labcorp Holdings Inc. by 18.2% in Q4, now owning 45,312 shares worth $11.4 million. This comes as Labcorp reported stronger-than-expected Q1 earnings, with EPS of $4.25 and revenue of $3.54 billion, and announced a quarterly dividend of $0.72 per share. Analyst ratings currently average a "Moderate Buy" for the company.
Have Guardant Health Insiders Been Selling Stock?
Guardant Health (NASDAQ:GH) has seen significant insider selling recently, with Co-CEO AmirAli Talasaz selling shares worth $5.0m and co-founder Helmy Eltoukhy selling $18m worth below the current price. While insiders own a healthy 3.8% of the company, the consistent selling without corresponding purchases raises caution for potential investors. The article highlights that such selling is a weak signal but suggests that insiders might view current valuations as high.
Bessemer Group Inc. Acquires 209,947 Shares of Labcorp Holdings Inc. $LH
Bessemer Group Inc. significantly increased its stake in Labcorp Holdings Inc. (NYSE:LH) by 114.6% in the fourth quarter, purchasing an additional 209,947 shares to bring its total holding to 393,189 shares valued at approximately $98.6 million. Analyst sentiment for Labcorp remains positive, with a "Moderate Buy" consensus rating and a target price of $308, while the company recently reported strong quarterly earnings and announced a $0.72 per share quarterly dividend.
Labcorp Holdings Inc. stock underperforms Friday when compared to competitors
Labcorp Holdings Inc. (LH) stock fell 1.43% on Friday, closing at $250.40, underperforming the broader market. This marked the stock's third consecutive day of losses, as both the S&P 500 Index and the Dow Jones Industrial Average also experienced declines.
Veracyte Gains Medicare Coverage for Muscle-Invasive Bladder Cancer Recurrence Monitoring Test
Veracyte's TrueMRD Monitoring Test has received Medicare coverage for recurrence monitoring in patients with muscle-invasive bladder cancer (MIBC) following definitive treatment. This makes it Veracyte’s first molecular residual disease (MRD) commercial offering and the first commercially available whole-genome MRD test on the market. The test, which launches June 1, 2026, aims to improve early detection of recurrence and inform treatment decisions, especially as MIBC patients have a high recurrence rate within two years.
Hybrid Clinical Research Job at ICON | Life Science Graduates Must Apply!
ICON plc is hiring for a hybrid CDC II (Clinical Data Management) role in Bangalore, Chennai, and Trivandrum, seeking Life Science graduates. This opportunity focuses on clinical data review, validation, and analytics to
Labcorp Holdings Inc. $LH Shares Purchased by Thrivent Financial for Lutherans
Thrivent Financial for Lutherans increased its stake in Labcorp Holdings Inc. by 2.5% in the fourth quarter, now owning 577,027 shares valued at $144.8 million. Institutional investors collectively own 95.94% of the company. Analysts maintain a "Moderate Buy" consensus, with an average target price of $308, after Labcorp reported strong Q1 results and announced a quarterly dividend.
Labcorp stock (US50540R4092): Q1 earnings beat with $4.25 EPS
Labcorp reported stronger-than-expected Q1 2026 earnings, with adjusted EPS of $4.25 and revenue growth of 5.8% to $3.54 billion, surpassing analyst forecasts. The company's performance was driven by its core clinical laboratory testing and drug development services. Labcorp's significant exposure to the US healthcare system and its position in the diagnostics industry contribute to its resilience for investors.
Exagen Inc. (NASDAQ:XGN) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Exagen Inc. (NASDAQ:XGN) recently reported first-quarter results that surpassed analyst expectations for both revenue and narrower losses per share. Following these results, analysts have modestly updated their estimates, showing a slight increase in optimism regarding future losses, although revenue forecasts remain largely unchanged. The consensus price target for Exagen held steady at US$8.67, with expected revenue growth slowing compared to historical performance and industry peers.
Bioinformatics Platforms Market Is Going to Boom | • Illumina Inc • Thermo Fisher Scientific Inc • QIAGEN N.V
Worldwide Market Reports has released an in-depth study on the Bioinformatics Platforms Market, forecasting its size and trends from 2026-2033. The report, based on primary interviews and secondary data, analyzes growth drivers, opportunities, risks, and challenges, integrating SWOT and Porter's Five Forces analysis. It covers market segments by type, deployment mode, and application, and profiles key players like Illumina Inc., Thermo Fisher Scientific Inc., and QIAGEN N.V., providing regional coverage and strategic takeaways for decision-makers.
Onconetix (ONCO) highlights new Proclarix studies and U.S. PRIME trial
Onconetix (ONCO) has highlighted significant progress for its Proclarix® blood test, including two new peer-reviewed studies that demonstrate its effectiveness in reducing prostate cancer overdiagnosis and unnecessary biopsies, as well as its prognostic value. The company has also initiated the PRIME multi-center clinical validation study in the U.S. with Labcorp and reported early commercial traction in Europe, including nearly 100 tests in a UK screening initiative. This update emphasizes the growing clinical evidence and expanding geographic reach for Proclarix®.
Onconetix reports Proclarix peer-reviewed data and launches U.S. PRIME validation study with Labcorp
Onconetix has announced new peer-reviewed data for Proclarix and the initiation of a U.S. multi-center PRIME validation study with Labcorp, enrolling up to 500 men. Two papers highlighted Proclarix's ability to reduce overdiagnosis and predict active surveillance transition. The company is also expanding commercially in Europe, with Proclarix being offered in a U.K. screening initiative and a partner identified in Turkey.
Evaluating Labcorp Holdings (LH) After Expanded Epic Partnership And An 18% Estimated Valuation Gap
Labcorp Holdings (LH) is highlighted following an expanded partnership with Epic, integrating its diagnostic test menu into Epic's Aura platform. Despite recent soft share price performance, the company shows long-term gains and is considered 18% undervalued with a fair value of $310.06 per share. The valuation anticipates increased test volumes, improved margins through AI, and closer cost discipline, though risks like regulatory changes and competition exist.
Swiss Life Asset Management Ltd Has $4.70 Million Stock Holdings in Labcorp Holdings Inc. $LH
Swiss Life Asset Management Ltd significantly reduced its stake in Labcorp Holdings Inc. by 49.5% in the fourth quarter, now holding 18,713 shares valued at $4.7 million. Despite insider sales totaling approximately $4.52 million within the last 90 days, Labcorp reported strong quarterly results, beating EPS expectations and achieving $3.54 billion in revenue. The company maintains an overall "Moderate Buy" rating from analysts with an average target price of $308.00.
Labcorp stock (LH): Q1 earnings beat with $4.25 EPS
Labcorp (NYSE: LH) exceeded Q1 2026 earnings expectations, reporting an adjusted EPS of $4.25 against an analyst consensus of $4.09, and revenue growth of 5.8% to $3.54 billion. The company's strong performance was driven by its diagnostics segment, particularly in oncology, women's health, and infectious disease testing, alongside its drug development services. Labcorp's stock closed at $257.13 on May 12, 2026, and year-to-date performance shows a 1.4% increase, reflecting resilient growth in its core businesses.
Insight Molecular Q1 2026 Earnings Call Transcript
Insight Molecular (NASDAQ: IMDX) held its Q1 2026 earnings call, detailing the submission of GraftAssuredX to the FDA in March 2026 and positive market research outcomes. The company projects Q2 2026 revenue of $250,000 and a high cash burn of over $9 million, expected to decrease in the latter half of the year. Key initiatives include expanding the Galactic Registry study, targeting regulatory compliance in Europe and the UK, and moving into heart transplant testing with the goal of long-term gross margins around 70%.
Labcorp Holdings Insider Sold Shares Worth $1,502,314, According to a Recent SEC Filing
An insider at Labcorp Holdings recently sold shares worth $1,502,314, as detailed in a recent SEC filing. The transaction involved the sale of 6,100 shares of common stock at a price of $246.28 per share by Executive Vice President & CAO, Kerrii B. Anderson. Following this sale, Anderson still directly owns 19,531 shares of the company.
Evaluating Labcorp Holdings (LH) After Expanded Epic Partnership And An 18% Estimated Valuation Gap
Labcorp Holdings (LH) recently expanded its partnership with Epic, integrating its diagnostic test menu into Epic's Aura platform to streamline ordering and results for healthcare systems. Despite recent short-term share price softening, the company is estimated to be 18% undervalued with a fair value of $310.06 per share. This valuation is supported by anticipated growth from innovative tests, enhanced operational efficiencies through AI and technology, and tighter cost discipline, although potential risks from regulatory changes or increased competition could challenge this upside.
BeyondSpring (NASDAQ: BYSI) swings to $6.7M net loss as SEED ops weigh
BeyondSpring (NASDAQ: BYSI) reported a consolidated net loss of $6.7 million for Q1 2026, a significant swing from a $1.2 million net income in Q1 2025, primarily due to a $4.3 million loss from discontinued SEED operations and the absence of a $7.0 million gain from a SEED share sale seen in the prior year. The company's continuing operations recorded a $2.4 million net loss, with research and development expenses increasing while general and administrative costs decreased. BeyondSpring ended the quarter with $7.9 million in cash and short-term investments from continuing operations, and expects additional inflows from future SEED preferred share sales, with management exploring various financing and strategic alternatives.
MDxHealth (NASDAQ: MDXH) posts Q1 2026 growth and issues new 2026 guidance
MDxHealth reported Q1 2026 revenue of $27.4 million, a 13% increase year-over-year, alongside an operating loss of $7.3 million and a net loss of $8.9 million. The company announced it would discontinue its Resolve UTI business and close its Plano, Texas lab to focus on prostate cancer diagnostics and the ExoDx acquisition. MDxHealth also issued new 2026 core cancer revenue guidance of $110–115 million, representing 20–26% growth, and is contesting a $10.4 million Medicare recoupment decision related to historical Resolve claims.
Expanded collab brings full Labcorp test menu to Epic platform
Epic and Labcorp have expanded their collaboration to integrate Labcorp's full diagnostic test menu into Epic's Aura platform. This integration will enable clinicians to order and receive results for a wide variety of lab tests directly within their Epic workflow, aiming to streamline processes and reduce administrative burdens. The partnership also emphasizes interoperability, aligning with broader industry initiatives to improve data exchange in healthcare.
Labcorp Holdings Inc. stock outperforms competitors despite losses on the day
Labcorp Holdings Inc. (LH) shares decreased by 1.14% to $254.42 on Wednesday, despite outperforming competitors. The broader market saw the S&P 500 Index rise by 0.58%, while the Dow Jones Industrial Average fell by 0.14%. This decline ended a two-day winning streak for Labcorp stock.
Labcorp stock (US50540R4092): Enhances Partnership with Epic for Lab Services
Labcorp has strengthened its collaboration with Epic, a major electronic health records platform, to enhance lab services integration and improve efficiency for healthcare providers across the US. This partnership aims to streamline diagnostic workflows and leverage technological advancements in diagnostics. The move highlights Labcorp's strategic focus on digital integration in the healthcare sector, which is positioned to drive long-term growth in test volumes and service adoption.
ICON's New Texas Hub Aims to Reshape Early Phase Drug Trials
ICON plc has expanded its U.S. operations with a new Clinical Research Unit in San Antonio and satellite clinics, aiming to accelerate early-phase drug trials. This strategic move responds to the growing CRO market and increasing R&D spending, integrating clinical, laboratory, and pharmacy operations to enhance efficiency, reduce delays, and improve data quality. The expansion also focuses on patient-centric design and recruitment diversification, positioning ICON as a leader in pharmaceutical development and bolstering San Antonio's life sciences sector.
Labcorp (NYSE: LH) CEO sells 5,903 shares under 10b5-1 plan
Labcorp's President & CEO, Adam H. Schechter, sold 5,903 shares of Common Stock at $254.50 per share through an open-market transaction on May 11, 2026. This sale was conducted under a pre-established Rule 10b5-1 trading plan. Following the transaction, Schechter directly holds 107,234 shares of Labcorp common stock.
New Bright Horizons service helps workers manage aging parents, care challenges
Bright Horizons (NYSE: BFAM) has partnered with Homethrive to launch a new "Care Advising" solution, aimed at helping employers support working families with complex caregiving needs. This unified platform addresses challenges such as aging-in-place, Medicare navigation, neurodiversity, and end-of-life planning. The collaboration seeks to streamline caregiving support for employees, as caregiving attrition is a significant reason workers leave their jobs.
